Volt PFA System
ABBOTT MEDICAL · Decision date Dec 19, 2025
What did the FDA approve?
FDA records P250022 as an original PMA application. The recorded decision is approval, dated Dec 19, 2025.
FDA approval order statement
approval for the Volt PFA System. This device is indicated for: The Volt PFA Catheter, Sensor Enabled is indicated for the treatment of symptomatic, recurrent, drug-refractory paroxysmal or persistent (episode duration less than one year) atrial fibrillation when used in conjunction with a compatible pulsed field ablation (PFA) generator. The catheter is compatible with the EnSite X EP System. The Current PFA Generator is indicated for use with compatible ablation catheters for the treatment of cardiac arrhythmias.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 19, 2025
Regulatory record facts
- Identifier
- P250022
- Regulatory pathway
- Premarket approval application
- Applicant
- ABBOTT MEDICAL
- Product code
- QZI
- Decision code
- APPR
- Decision date
- Dec 19, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Abbott Medical
- Product code
- QZI
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250022 received
Application receipt date recorded by FDA.
P250022 · FDA decision
APPR
P250022/S009 · Related supplement
Volt PFA Catheter, Sensor Enabled
P250022/S012 · Related supplement
VOLT PFA CATHETER, SENSOR ENABLED
P250022/S002 · Related supplement
Volt PFA System
Timeline entries are records held by MedtechLedger for P250022. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250022
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Volt PFA Catheter, Sensor EnabledP250022/S009 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
VOLT PFA CATHETER, SENSOR ENABLEDP250022/S012 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
Sphere-9 Catheter and Affera Ablation SystemP240013/S028 | Medtronic, Inc. | PMA supplement | Oct 6, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 5050 Nathan Ln. N., Plymouth, MN, 55442
Sources and methodology
- Original FDA record: P250022
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
